Fresenius Medical Care's shares experienced a significant drop of over 7% following the release of its 2026 outlook, which projects broadly flat revenue and operating income.
This forecast contrasts with a strong 2025 performance, where adjusted operating income rose 27% and revenue increased by 2%. The company also announced cost-saving measures, raising its target to €1.2 billion by 2027 and expecting €250 million in savings in 2026.
Despite these efforts, analysts like Jefferies expressed disappointment, anticipating higher growth and noting headwinds. The company's U.S. performance showed flat same-market treatment growth for the year.
Fresenius Medical Care is planning a large-scale rollout of its 5008X CAREsystem in the United States in 2026.
Data sourced from public RSS feeds and News APIs.